Northwest Biotherapeutics announced that it really possesses 30 clinical trial websites open and recruiting in the United States within its ongoing Phase 2 clinical trial of DCVax®-L immune procedures for Glioblastoma multiforme (GBM), the foremost lethal type of brain cancer. The firm delivered this milestone ahead of time, as the Firm had promoted to arrive it by the end of Q1, 2012. The organization likewise met or exceeded its plans throughout three concluding quarters (Q2, Q3 and Q4 of 2011), as formerly declared.
The Company intentions to continue including clinical trial websites, and will insist on to have at least 40 websites open and registering from the end of Q2, 2012. The firm will additionally keep chasing its programs in Europe. The accessible and active trial websites are compiled on the U.S. Government's website, www.clinicaltrials.gov, and on NW Bio's website, www.nwbio.com.
As formerly reported, the Company's improvement is continuing to reflect the developing interest from both physicians and individuals, as well as a growing awareness of the constructive data coming from the Company's before clinical trials for GBM brain cancer. In such trials, patients that received DCVax® showed a median existence of 3 years in comparison to median existence of 14.6 months for affected individuals that acquired standard of attention (surgery, radiation and chemotherapy). Individuals that received DCVax® also experienced a substantially even longer time to tumor recurrence: a medium of 2 years, in comparison to 6.9 months in patients that received commonplace of care. DCVax® was well tolerated, without toxic negative effects.Linda Powers, CEO of NW Bio, said that "Along with our recently announced cooperation in the American Red Cross, the ongoing growth of our test’s websites help build a broad community to bring DCVax® to sufferers through the entire country. We are precisely pleased to get the continuing growth of great interest in DCVax® throughout medical neighborhood."
No comments:
Post a Comment